LTP impairment by fractalkine/CX3CL1 in mouse hippocampus is mediated through the activity of adenosine receptor type 3 (A3R)

J Neuroimmunol. 2009 Oct 30;215(1-2):36-42. doi: 10.1016/j.jneuroim.2009.07.016. Epub 2009 Aug 26.

Abstract

We have examined how the chemokine fractalkine/CX(3)CL1 influences long-term potentiation (LTP) in CA1 mouse hippocampal slices. Field potentials (fEPSPs) were recorded upon electrical stimulation of Schaffer collaterals. It was found that application of CX(3)CL1 inhibits LTP when present during the critical induction period. LTP impairment (i) failed to occur in CX(3)CR1 deficient mice (CX(3)CR1(GFP/GFP)) and in the presence of okadaic acid (OA); (ii) required the activation of adenosine receptor 3 (A(3)R), since it was prevented in A(3)R-deficient mice or by MRS1523, a selective A(3)R antagonist. Together, these findings indicate that CX(3)CL1 inhibits hippocampal LTP through A(3)R activity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chemokine CX3CL1 / physiology*
  • Hippocampus / immunology*
  • Hippocampus / metabolism
  • Humans
  • In Vitro Techniques
  • Long-Term Potentiation / immunology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neural Inhibition / immunology
  • Receptor, Adenosine A3 / metabolism*
  • Receptor, Adenosine A3 / physiology

Substances

  • Chemokine CX3CL1
  • Receptor, Adenosine A3